Volume 152, Issue 1, Pages (January 2019)

Slides:

Advertisements

Similar presentations

ABO-incompatible kidney transplantation Kota Takahashi, Kazuhide Saito Transplantation Reviews Volume 27, Issue 1, Pages 1-8 (January 2013) DOI: /j.trre

Advertisements

Combined PTEN Mutation and Protein Expression Associate with Overall and Disease- Free Survival of Glioblastoma Patients Jie Xu, Zhaoli Li, Jilin Wang,

Volume 144, Issue 1, Pages (January 2017)

Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery David Palma, Otto.

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.

Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma

PUBLISH ONLY Journal of Thoracic Oncology

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)

Rajmohan Murali, Rachel N. Grisham, Robert A. Soslow

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

Pain in cancer survivors; filling in the gaps

Volume 145, Issue 2, Pages (May 2017)

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 148, Issue 1, Pages (January 2018)

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Volume 146, Issue 1, Pages (July 2017)

Volume 152, Issue 1, Pages (January 2019)

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

PUBLISH ONLY Journal of Thoracic Oncology

Volume 147, Issue 1, Pages (October 2017)

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Volume 152, Issue 1, Pages (January 2019)

Antibiotic De-Escalation

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Volume 152, Issue 1, Pages (January 2019)

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Volume 130, Issue 1, Pages (July 2013)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 152, Issue 1, Pages (January 2019)

Treatment of Colorectal Cancer

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

International Thymic Malignancies Interest Group: A Way Forward

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 124, Issue 1, Pages (January 2012)

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 115, Issue 1, Pages (October 2009)

Volume 152, Issue 3, Pages (March 2019)

Presentation transcript:

Volume 152, Issue 1, Pages 26-30 (January 2019) Adjuvant therapy in stage III endometrial cancer confined to the pelvis Reem Albeesh, Guy-Anne Turgeon, Joanne Alfieri, José João Mansure, Lili Fu, Jocelyne Arseneau, Xing Zeng, Kris Jardon, Lucy Gilbert, Luis Souhami Gynecologic Oncology Volume 152, Issue 1, Pages 26-30 (January 2019) DOI: 10.1016/j.ygyno.2018.11.002 Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 1 Overall survival (A), disease-free survival (B) and disease-specific survival (C) for all patients. Gynecologic Oncology 2019 152, 26-30DOI: (10.1016/j.ygyno.2018.11.002) Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 2 Overall survival (A), disease-free survival (B) and disease-specific survival (C) for patients with grade 3 disease. Gynecologic Oncology 2019 152, 26-30DOI: (10.1016/j.ygyno.2018.11.002) Copyright © 2018 Elsevier Inc. Terms and Conditions